Core Insights - Inogen, Inc. reported an adjusted loss per share of 15 cents for Q4 2025, which is an improvement from a loss of 24 cents in the same quarter last year and better than the Zacks Consensus Estimate of a loss of 36 cents per share [1][10] - The company’s revenues for the fourth quarter were $81.7 million, reflecting a 2% year-over-year increase, although this figure fell short of the Zacks Consensus Estimate by 0.3% [2][10] Revenue Breakdown - U.S. rental revenues were $13.1 million, down 4.5% year-over-year, attributed to a less favorable reimbursement mix and a decrease in the number of patients on service [5] - Total sales revenues reached $68.6 million, up 3.4% from the prior year, with U.S. sales at $36.1 million (down 5.1%) and international sales at $32.5 million (up 14.8%) [6][10] Margin Analysis - Inogen's adjusted gross profit decreased by 3.3% year-over-year to $38 million, with the adjusted gross margin contracting by 260 basis points to 46.5% [7] Expense Management - Sales and marketing expenses decreased by 4.4% to $23.1 million, R&D expenses fell by 9.9% to $5.3 million, and general and administrative expenses decreased by 8.5% to $16.1 million [8] - Adjusted operating expenses totaled $41.4 million, down 5.2% year-over-year, with an adjusted operating loss of $6.2 million compared to $7.4 million in the prior year [8] Financial Position - At the end of Q4 2025, Inogen had cash and cash equivalents of $103.7 million, a slight decrease from $106.5 million at the end of Q3 2025 [9][11] - The company reported no debt on its balance sheet and cumulative net cash used in operating activities was $11.2 million [11] Future Guidance - For Q1 2026, Inogen expects revenues to align with Q1 2025, with the Zacks Consensus Estimate at $90.8 million [12] - For the full year 2026, the revenue outlook is between $366 million and $373 million, indicating approximately 6% growth at the midpoint compared to 2025 [12] Strategic Developments - Inogen expanded its product portfolio with the launch of new products aimed at the sleep therapy market and initiated a limited market release of a new airway clearance device [14][15] - The company also launched a new patient portal to enhance digital health capabilities and announced a strategic collaboration with Yuwell Medical to expand its product offerings in China [15]